△◠○◡◇ Fabulations
▩ Approaches
<<<< about:: >>>>
ʬʭ Multi Filter
- Materials
  Approaches
  Fabulations
  People/Orgs
  Bits of Narration

⌕⌕ Search Materials

84 object Results

Sort by:

Identifier

Title

Sort order:

Ascending
Descending

Start Over

Download results as:

Checklist
PDF (thumbnails)
Excel (basic information)
PowerPoint (basic information)

approach:

ZQQW4XX2
Positivrat Schweiz - Misère rund um die Hepatitis-C-Therapien: Atupri bezahlt à tout prix nicht!

ZF5HP5PV
The latest patent application of Hepatitis C drug Sovaldi of Gilead is rejected in China | Lexology

Z5AGNYET
Interferon production by genetic engineering.

YURQAGXI
Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy

YFLSD3I9
Genetic organization and diversity of the hepatitis C virus.

YECHCX4Q
Biological Medicine and the Survival of the Person

XMKJQXUP
GenBank. Nucleic Acids Res. 45(D1):D37-D42 (2017)

XJV92XD9
The Origin of Hepatitis C Virus

W4E3GJKM
Depression, fatigue and neurocognitive deficits in chronic hepatitis C

VWAJD4BG
Handbook of Hepatitis C

VSHTX9XY
Modest_Witness@Second_Millennium. FemaleMan_Meets_OncoMouse: Amazon.de: Donna J. Haraway, Thyrza Goodeve: Amazon.de

VRFDF6GQ
Corporate Overview - Pharmasset, Inc.

T2JGMH7T
Treatment of chronic hepatitis C with PEGylated interferon and ribavirin

SVVXKA89
Hepatitis C: Epidemiologie, natürlicher Verlauf und Diagnostik

STZDLGLN
Interferon Set to Treat Hepatitis

SNDKI86X
Natco tries to block hepatitis C patent in India / General / Generics / Home - GaBI Online - Generics and Biosimilars Initiative

RXEDQ5AD
Die Problematik der Nutzung von Zwangslizenzen durch Staaten ohne eigene Pharmaindustrie: Zur instrumentellen Umsetzung von Art. 6 der Erklärung zum TRIPs und zum öffentlichen Gesundheitswesen#

RGJIV865
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

R7WUJHP6
Hepatitis C die stille Epidemie: Eine Informationsbroschüre der forschenden pharmazeutischen Firmen der Schweiz

QTTH8PSL
Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

QS3KDFMI
Chiron challenged on hepatitis-C patent

QPG7B895
Gilead to Buy Pharmasset for $11 Billion to Win in Hepatitis

QM3G8NJF
Molecular Biopolitics, Somatic Ethics and the Spirit of Biocapital

QBEBZJAN
Human tumor-associated viruses and new insights into the molecular mechanisms of cancer

Q9RNVVN9
India announces new trademark, patent policy amid global pressure

Q7V5BLE6
Compulsory Licences Needed For Affordable Hepatitis C Innovative Drug Regimens

PNXGJUS2
Heilmittel mit finanziellen Nebenwirkungen

P58K5S32
Gilead bets $11 billion on hepatitis in Pharmasset deal

NN5CZW2U
Hepatitis C

NHDVXHCL
Transformation of Pseudomonas putida and Escherichia coli with plasmid-linked drug-resistance factor DNA.

Nationalrat_17.3027
Nationalrat Interpellation 17.3027 | Ist die Sicherheit der Medikamente auf dem Gesundheitsmarkt Schweiz noch gewährleistet?

N9ACJJMZ
Global Access | Gilead

MQ5C3IXF
Eine Packung Pillen für 19’000 Franken

KNUKHFTN
Hepatitis C

KK9MEU5V
Pharco Pharmaceuticals

K9P8T5XG
Hepatitis C wait is over - Leo Messi vs. Melanie. #StopTheWait

Filter by

object type

Book Sections (4)

Conference Papers (1)

Journal Articles (26)

Newspaper Articles (8)

Video Recordings (1)

person

United States Securities and Exchange Commission (SEC) (1)

Abaza, Deya (1)

HCV Advocate (1)

Aeple, Natalia (1)

Andino, Raul (1)

Atlan, Henri (1)